Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates.

PARVAX is a genetic vaccine platform based on an adeno-associated vector that has demonstrated to elicit potent, durable, and protective immunity in nonhuman primates (NHPs) after a single dose. Here, we assessed vaccine immunogenicity following a PARVAX prime-boost regimen against SARS-CoV-2. In mice, a low-dose prime followed by a higher-dose boost elicited potent neutralizing antibody responses and distinct cross-reactivity profiles, depending on the antigen used in the booster vaccine.

Bis(ethyl-enedi-ammonium) μ-ethyl-enedi-aminetetra-acetato-1κ ,,':2κ '',','''-bis-[tri-oxidomolybdate(VI)] tetra-hydrate.

The title compound, (CHN)[(CHNO)(MoO)]·4HO, which crystallizes in the monoclinic 2/ space group, was obtained by mixing molybdenum oxide, ethyl-enedi-amine and ethyl-enedi-amine-tetra-acetic acid (Hedta) in a 2:4:1 ratio. The complex anion contains two MoO units bridged by an edta anion. The midpoint of the central C-C bond of the edta anion is located on a crystallographic inversion centre.

Octa-kis(di-butyl-ammonium) deca-molybdate(VI).

In the title salt, (CHN)[MoO], the [MoO] polyanion is located about an inversion centre and can be considered as a -type octa-molybdate anion to which two additional MoO tetra-hedra are linked common corners. The [MoO] polyanions are packed in rows extending parallel to [001] and are connected to the di-butyl-ammonium counter-cations through N-H⋯O hydrogen-bonding inter-actions.

Saccharomyces cerevisiae fungemias: how heterogenous is their management?

Saccharomyces cerevisiae is a yeast used mainly as a probiotic for prevention or treatment of diarrhoea. However, the prevalence of S. cerevisiae fungemia has risen over the past years, notably among patients with predisposing factors.